Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Filed in November 2022, this Form 8-K reports Aprea Therapeutics’ resolution of a Nasdaq continued-listing deficiency. The relevant financial information is from the Form 10-Q for the period ended September 30, 2022.
Key Financial and Liquidity Metrics
- Stockholders’ equity was approximately $26.6 million as of September 30, 2022.
- Nasdaq’s minimum stockholders’ equity requirement for continued listing under Listing Rule 5450(b)(1)(A) is $10.0 million.
- This filing does not provide revenue, net income or loss, operating cash flow, cash balance, margins, debt, or additional liquidity metrics.
Material Change Versus the Prior Comparable Period
On August 15, 2022, Nasdaq notified the Company that it did not meet the $10.0 million minimum stockholders’ equity requirement. Based on the Company’s September 30, 2022 Form 10-Q, Nasdaq determined that the Company had regained compliance. The filing does not provide a prior-period equity figure or explain the specific changes that restored compliance.
Guidance, Outlook, Risks, and Unusual Items
- The Company is no longer identified in this filing as failing to satisfy the Nasdaq stockholders’ equity requirement.
- No financial guidance or operating outlook is provided.
- The filing does not describe contingencies, financing plans, or other unusual items beyond the Nasdaq deficiency and subsequent compliance determination.
Important Facts to Verify
- Verify the approximately $26.6 million stockholders’ equity figure in the Form 10-Q for the quarter ended September 30, 2022.
- Confirm the effective date and scope of Nasdaq’s compliance determination.
- Review subsequent filings for any renewed listing deficiencies, financing activity, or changes in liquidity.
- Note that the Form 8-K is dated November 15, 2022, while the signature is dated November 16, 2022.